Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf

Martin O Bergo1, Bryant J Gavino, Christine Hong

  • 1Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. mbergo@gladstone.ucsf.edu

Insights

Inactivating Isoprenylcysteine carboxyl methyltransferase (Icmt) inhibits K-Ras and B-Raf-induced cancer cell growth. This occurs by reducing RhoA levels and increasing p21(Cip1), highlighting Icmt as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Isoprenylcysteine carboxyl methyltransferase (Icmt) methylates CAAX proteins, crucial for Ras and Rho protein function.
  • Carboxyl methylation of Ras proteins is essential for their plasma membrane localization and oncogenic signaling.

Purpose of the Study:

  • To investigate the role of Icmt in K-Ras and B-Raf-driven oncogenic transformation.
  • To determine if Icmt is a viable therapeutic target for K-Ras and B-Raf-induced malignancies.

Main Methods:

  • Generated K-Ras-Icmt(Delta/Delta) fibroblasts by inactivating Icmt in cells expressing activated K-Ras.
  • Assessed oncogenic transformation using soft agar assays and a nude mouse model.
  • Analyzed protein levels, phosphorylation, and cell cycle regulators (e.g., p21(Cip1)).

Main Results:

  • Icmt inactivation significantly inhibited K-Ras-induced cell growth and transformation.
  • Reduced RhoA protein levels and increased p21(Cip1) were observed upon Icmt deletion.
  • Deletion of p21(Cip1) rescued the transformation phenotype in Icmt-deficient cells.
  • Icmt inactivation also blocked transformation driven by an oncogenic B-Raf mutant.

Conclusions:

  • Icmt plays a critical role in K-Ras and B-Raf-mediated oncogenesis.
  • Targeting Icmt effectively inhibits cancer cell growth and transformation.
  • Icmt represents a promising therapeutic target for K-Ras and B-Raf-driven cancers.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...